Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 11/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834525 | 0.84 | L3MBTL1 (0.88) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL78852 | 0.83 | L3MBTL1 (0.78) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL18868405 | 0.83 | L3MBTL1 (1.00) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL166144 | 0.83 | L3MBTL1 (0.70) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL5114223 | 0.82 | L3MBTL1 (0.81) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL6836614 | 0.81 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL16906823 | 0.81 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL2770819 | 0.81 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL12909782 | 0.81 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL1863584 | 0.81 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006231-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2014-06-19 | — | — | US | disclosed |
| US-8466142-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | COASY, CXCR4, CETP | L3MBTL1 2157/4885GAA 2588/4885MAPT 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.